| pubmed-article:17290408 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0008479 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0567416 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0019731 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0024348 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C0368692 | lld:lifeskim |
| pubmed-article:17290408 | lifeskim:mentions | umls-concept:C1541478 | lld:lifeskim |
| pubmed-article:17290408 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17290408 | pubmed:dateCreated | 2007-4-17 | lld:pubmed |
| pubmed-article:17290408 | pubmed:abstractText | Treatment of chondrosarcomas is limited to resection because these tumors are unresponsive to standard adjuvant treatments, such as chemotherapy and radiation. We have previously shown that high-grade chondrosarcomas express unspecified members of the Melanoma Antigen (MAGE) gene family. We show here that FS human chondrosarcoma (FS) cells express MAGE-A3 gene and HLA-A1 molecules. In vitro assays show that a cytolytic T-lymphocyte clone (CTL) specific for a MAGE-A3 peptide presented by HLA-A1 specifically lysed FS chondrosarcoma cells. Addition of antigenic peptide did not increase the susceptibility of FS cells to CTL mediated lysis, suggesting that HLA-A1 expression by the chondrosarcoma cells limited their susceptibility to lysis by the anti-MAGE-A3 CTL clone. Incubation of FS cells with 50 U/mL interferon-gamma increased surface expression of HLA class-I molecules, increased their susceptibility to lysis, and had no effect on MAGE-A3 gene expression. These results suggest that immunotherapy targeted against chondrosarcoma cells is possible. | lld:pubmed |
| pubmed-article:17290408 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17290408 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17290408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17290408 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17290408 | pubmed:month | May | lld:pubmed |
| pubmed-article:17290408 | pubmed:issn | 0736-0266 | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:MeitnerPatric... | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:TerekRichard... | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:BlockJoel AJA | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:BlumanEric... | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:CouliePierre... | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:SunXiaojuanX | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:MachanJasonJ | lld:pubmed |
| pubmed-article:17290408 | pubmed:author | pubmed-author:LinChouzaoC | lld:pubmed |
| pubmed-article:17290408 | pubmed:copyrightInfo | (c) 2007 Orthopaedic Research Society. | lld:pubmed |
| pubmed-article:17290408 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17290408 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:17290408 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17290408 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17290408 | pubmed:pagination | 678-84 | lld:pubmed |
| pubmed-article:17290408 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:meshHeading | pubmed-meshheading:17290408... | lld:pubmed |
| pubmed-article:17290408 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17290408 | pubmed:articleTitle | Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules. | lld:pubmed |
| pubmed-article:17290408 | pubmed:affiliation | Department of Orthopaedic Surgery, Brown University, Providence, Rhode Island, USA. | lld:pubmed |
| pubmed-article:17290408 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17290408 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
